In this study, we have provided the experimental evidence that MUC4, a transmembrane oncogenic glycoprotein aberrantly expressed by pancreatic cancer (PC) cells, interacts with galectin-3 present on endothelial cells. This interaction is specific for galectin-3 and involves the T-antigen present on MUC4. We also demonstrate that the adhesion of PC cells to endothelial HUVECs is dependent on MUC4 expression and presence of exogenous galectin-3, but not the intracellular galectin-3. Quantitative analysis of serum galectin-3 levels in samples from PC patients shows that galectin-3 levels are significantly elevated in PC patients with metastatic disease compared to those with localized disease and healthy controls. The interaction between serum galectin-3 and Research.
Introduction

Pancreatic cancer (PC) is the fifth leading cause of adult cancer death in the United
States, with a five-year survival rate of only 1-4% [1] . PC is an extremely aggressive tumor, with early metastases to both lymph nodes and distant organs [2] . The invasive properties PC cells lead to the growth of the tumor in major abdominal vessels, the neighboring organs, and the retroperitoneal bed, which makes curative resection often impossible [2, 3] . During the processes of invasion and metastasis, tumor cells leave their primary site, invade the surrounding extracellular matrix and the endothelium, penetrate the blood and lymph vessels, and finally attach and proliferate at a secondary site [2] .
However, little is known of the molecular and cellular mechanisms that contribute to this cascade of events that leads to local tumor invasion and the formation of distant metastases. A better understanding of the molecular mechanisms behind PC metastasis will help to develop newer, more efficacious anti-cancer therapies. The normal cell expresses a variety of cell adhesion molecules on its surface. These receptor molecules are involved in cell-to-cell communication and characterize the cell's position and function in the community with other cells and the extracellular matrix [2, 4] . During malignant cell transformation, the pattern of surface molecules and their activity can be dynamically changed. Thus, the cancer cells develop the ability to disrupt and invade normal tissue structures and finally form metastases in distant organs [5, 6] .
Haematogenous metastasis is a multi-step process and includes the detachment and release of tumor cells into the circulation, their adhesion to the endothelial wall of target tissues and either local growth or invasion through the microvascular wall and proliferation in the target organ parenchyma [7] . It is a well Several studies have shown that blood-borne tumor cells mediate their adhesion to the endothelium by using mechanisms similar to those adopted by leukocytes. Initial weak or transient contacts between cancer cells and the endothelium (docking) are likely to be mediated by carbohydrate-carbohydrate reorganization [8, 9] . This transient attachment further induces molecular changes in both the attached tumor cells and the endothelium by altering the expression and/or the localization of various permanent adhesion receptors (e.g. integrins and cadherins) and their corresponding ligands, leading to subsequent strong attachment (locking) of tumor cells to the endothelial surface [10] .
MUC4 mucin is a high-molecular-weight glycoprotein which is aberrantly expressed by PC cells but not by the non-neoplastic ducts. Structurally, MUC4 consists of two subunits: the large extra-cellular subunit, MUC4α, and the transmembrane subunit, MUC4β. Specifically, the mucin-like MUC4α subunit is heavily O-glycosylated [11] . Previous studies from our laboratory have shown that MUC4 potentiates PC cell proliferation, survival, invasion, and distant organ metastasis [11] [12] [13] [14] . Due to the presence of many carbohydrate moieties on its surface, MUC4 is a potential binding partner for different carbohydrate binding proteins including galectin-3. galectin-3, a member of the β-galactoside-binding family of lectins has emerged as a major player in cancer metastasis in general and PC in particular [15, 16] . Lurisci et al. had earlier
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Material and Methods
Galectin-3 recombinant protein (rGal-3) and anti-galectin-3 antibody
Human Galectin-3 cDNA was obtained from the American Type Culture Collection (ATCC). A double-digested with EcoRI and Pst I fragment was sub-cloned into pUC19
and transformed into E.coli mrf' cells. 
Cell culture
The human PC cell lines CD18/HPAF and Colo357 were cultured as before [16] . Human umbilical vein endothelial cells (HUVEC) were obtained from ATCC and were cultured as described previously [17] .
Immunoprecipitation and immunoblot analysis
Immunoprecipitation, SDS-PAGE, and immunoblotting analysis were done as previously described [11, 18] . Lysates from CD18/HPAF and Colo357 cells were utilized for immunoprecipitation. The immunoprecipitants were electrophoretically resolved on 2% agarose (for MUC4) or 15% polyacrylamide gel (for galectin-3). Antibodies, mouse anti-MUC4 monoclonal antibody at a concentration of 1.87µg/ml [18] and rat anti-galectin-3
(described previously) were used for the analysis. For immunoprecipitation, isotypematched mouse and rat IgG were used as negative controls.
Galectin binding assay
Cells were harvested and resuspended at a density of 2. 
Determination of serum galectin-3 levels by sandwich ELISA
Galectin-3 levels in serum were measured quantitatively by sandwich ELISA using the DuoSet ELISA kit for human Galectin-3 (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. ELISA plates were read at 450 nm, and data collected was analyzed using the SOFTMAX PRO software (Molecular Devices Corp., Sunnyvale, CA). Data were analyzed by using the MedCalc for Windows version 9.6.4.0 software (MedCalc Software, Mariakerke, Belgium). Variables were compared by using the twotailed Student's t-test. P value < 0.05 was considered as statistically significant. with localized disease. The mean galectin-3 levels were significantly higher in PC patients compared to that in healthy controls (p<0.05, Table 1 ). Further, among PC patients, serum galectin-3 levels were significantly (p<0.05) higher in those with metastatic PC than in those with localized disease.
Cell adhesion to HUVECs
MUC4 interacts with galectin-3 in PC cells
MUC4 is overexpressed in PC cells and has an extensively O-glycosylated extracellular portion that harbors many carbohydrate structures, which might interact with carbohydrate binding proteins like galectin-3. To investigate whether an interaction exists between MUC4 and galectin-3, we analyzed two MUC4 
Specific binding of MUC4-expressing cells to galectin-3
In order to determine the specificity of MUC4-galectin-3 interaction, a binding assay was performed. Recently, we have generated a MUC4-knockdown model in CD18/HPAF, MUC4 overexpressing PC cells [20] . This model is comprised of a scrambled shRNAexpressing pooled population (CD18/HPAF-Scr) and MUC4-target shRNA-expressing pooled population (CD18/HPAF-siMUC4), exhibiting a >80% decrease in the expression of MUC4 as compared to CD18/HPAF-Scr cells [10] . The binding assay was performed on galectin-3 coated plates. The CD18/HPAF-siMUC4 cells showed a significant decrease in binding to galectin-3 coated plates in comparison to CD18/HPAF-Scr cells (p <0.05). However, binding to galectin-1 was not significantly altered ( Figure 2A ).
MUC4 carries T antigen structures on its surface, and lactose competitively inhibits
MUC4-galectin-3 binding
For a direct interaction between MUC4 and galectin-3, MUC4 should carry galectin-3 binding sites on its surface. T antigen, a core 1 mucin glycan (Galβ1-3GalNAcαSer/Thr), is expressed on the outer surface of many cancer cells, including PC [8, 19] . Importantly, studies have shown that galectin-3 interaction with cancer-associated T antigen promotes cancer metastasis by enhancing the adhesion of circulating tumor cells to endothelial cells [17] . Among the proteins that are used to detect T antigen, peanut (Arachis hypogaea) agglutinin (PNA) is most widely used. Therefore, to check whether MUC4 has any T antigen structures on its surface or not, using PNA-Alexa Fluor 488 conjugates, an immunofluorescence experiment was carried out. In this experiment, CD18/HPAF-SCR cells showed more intense staining than CD18/HPAF-siMUC4 cells ( Figure 2B) . Further,
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Copyright © 2010 American Association for Cancer Research to check the specificity of galectin-3 and MUC4 interaction, a binding experiment was carried out ( Figure 2C ). We found that in contrast to MUC4 knock-down cells, the binding of scrambled RNA transfected CD18/HPAF cells was significantly inhibited in the presence of 50mM lactose (specific competitive inhibitor of galectin-3; p= 8.66E-11).
However, the binding was not affected in the presence of 50mM sucrose (as a negative control; p = 0.2).
MUC4 itself promotes adhesion of PC cells to HUVECs and the adhesion is enhanced in the presence of r-galectin-3
Glycans present on the cell surface glycoproteins, extend away from the cell membrane and put forth a first line of contact with nearby cells and substrates. To determine whether MUC4 itself plays any role in the adhesion of tumor cells to the endothelial cells (unstimulated) , we performed cell-cell binding assays in the absence of exogenous galectin-3. We observed that the number of CD18/HPAF-SCR cells bound to HUVECs was significantly higher than the number bound to the CD18/HPAF-siMUC4 cells (p=5.89E- Figure 3 ). The addition of exogenous galectin-3 significantly enhanced the binding of CD18/HPAF-SCR cells (but not CD18/HPAF SiMUC4 cells) to the endothelial (p=5.88E-05).
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As galectin-3 is a secreted protein, we also checked whether galectin-3 might is secreted into the culture media by the CD18/HPAF cells. However, the enriched culture media collected from these cells did not have a detectable amount of galectin-3 ( Figure   4A ). However, the total cell from both CD18/HPAF SCR and SiMUC4 cells had an equal amount of galectin-3 expression. Further, the confocal analysis also showed a similar Figure   4C ).
Galectin-3 alters MUC4 cell surface localization
To further understand the mechanisms by which serum-galectin-3-MUC4 interaction promotes tumor cell adhesion to the endothelium, we determined the effect of rGal-3 on cell surface localization of MUC4 ( Figure 5A ). After incubation of CD18/HPAF cells with rGal-3, the immunofluorescence experiment clearly showed clustering of MUC4 molecules on the surface of cancer cells ( Figure 5A ).
Discussion
Previous studies in our laboratory have established the role of MUC4 in the metastasis of PC cells [11, 12] . As discussed previously, a possible interaction between galectin-3 and MUC4 may be a promising mechanism behind MUC4-medated PC metastasis. Galectin-3 has been reported to interact with other membrane-bound mucins, MUC1 and MUC16 [21, 22] . Our present study shows that MUC4, a membrane bound mucin specifically interacts with galectin-3 and that MUC4-galectin-3 interaction modulates the adhesion of
PC cells to the endothelium in vitro.
Interaction Therefore, we hypothesize that the MUC4 present on the surface of CD18/HPAF-SCR cells might have induced translocation of endothelial galectin-3 to the cell surface and therefore promoted tumor cell to endothelial cell adhesion.
High serum galectin-3 concentrations have been reported in patients with metastatic colorectal, breast and pancreatic cancer [17] . In a large sample cohort, our present study also showed a similar observation of high serum galectin-3 levels in PC patients having metastasis compared to PC patients with localized disease and healthy
Copyright © 2010 American Association for Cancer Research controls. Taken together, these data suggest the possible importance of galectin-3 as a prognostic marker in PC patients. An earlier study through immunohistochemical analysis has shown that decrease in galectin-3 level in primary pancreatic tissue correlates with advanced stage of pancreatic cancer [30] . However, in the present study, the higher levels of serum galectin-3 that was detected in metastatic PC patients might be due to secretion of high amount of galectin-3 by tumor associated inflammatory and/or stromal cells [31, 17] . Thus, different levels of galecin-3 depending on various tumor microenvironments (primary tumor/ blood) might facilitate cancer metastasis trough different mechanisms. 
